-
Comparison of Rare Disease Patient and Caregiver Disease Burden in Terms of Economic, Social, and Interpersonal Impact and Impact on Quality Of Life: Results From an International Survey
Mar 10, 2025, 14:00 PM -
An Evaluation of PhlexNeuron, an Internal, Proprietary Artificial Intelligence (AI) Tool for Systematic Literature Review (SLR) Screening
Mar 10, 2025, 14:00 PM -
Patient and Physician Perspectives on Attributes of IO-Containing Perioperative Treatments in Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer (NSCLC)
Mar 10, 2025, 14:00 PM -
The Equitable Quality-Adjusted Life-Year
Mar 10, 2025, 14:00 PM -
The Potential Impact of COVID-19 Vaccine Efficacy and Vaccination Coverage on Health Equity Among United States (US) Older Adults
Mar 10, 2025, 14:00 PM -
2015-2024 Pricing Advantage of First-in-Indication Non-Oncology Orphan Products Versus Late Entrants and Recent Trends
Mar 10, 2025, 14:00 PM -
Benchmarking Duration of Injectable Medication Use: How do Claim Intervals Compare with Days Supply in the Real World?
Mar 10, 2025, 14:00 PM -
Healthcare Costs and Resource Utilization Associated With Knee Osteoarthritis and Obesity in the United States: A Retrospective Database Study
Mar 10, 2025, 14:00 PM -
Real-World Characteristics and Treatment Patterns With Nintedanib in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective US Claims Study
Mar 10, 2025, 14:00 PM -
Risk of Developing Diabetic Retinopathy and Diabetic Macular Edema in Patients With Insulin Therapy Vs Newer Oral Hypoglycemic Agents (SGLT2i and GLP-1)
Mar 10, 2025, 14:00 PM -
Evaluating the Economic and Environmental Impact of Reprocessed IPC Sleeves for VTE Prophylaxis: a Cost-Consequence Analysis
Mar 10, 2025, 14:00 PM -
Parametric Model Selection: Beyond AIC/BIC in Health Economic Context
Mar 10, 2025, 14:00 PM -
Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in US Adults Aged 60 Years with Cardiopulmonary Disease
Mar 10, 2025, 14:00 PM -
Patient Voice in Rare Disease Health Technology Assessments: Recent Trends in the Use of Qualitative Research in Reimbursement Submissions to Canada's Drug Agency
Mar 10, 2025, 14:00 PM -
Real-World Treatment Patterns, Healthcare Costs and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US using MarketScan® data
Mar 10, 2025, 14:00 PM -
Novel Therapies for Neurofibromatosis Type 1-Associated Inoperable Plexiform Neurofibromas: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
National and State Population-Level Estimated Economic Impact of Ocrelizumab on Cumulative Disabilities Avoided and Work Productivity Under Different Access Scenarios in the United States
Mar 10, 2025, 14:00 PM -
Disparities in Access to COPD Medications in Brazil - Impact of Geography and Socioeconomic Factors on Patient Travel Distances
Mar 10, 2025, 14:00 PM -
Adjusted Comparison of Amivantamab in Combination With Carboplatin Plus Pemetrexed From the PAPILLON Study Versus US Real-World Frontline Treatments in Patients With Advanced NSCLC Harboring EFGR Exon 20 Insertions
Mar 10, 2025, 14:00 PM -
Characteristics of Patients With Minimal Residual Disease (MRD) Testing for Solid Tumors in a United States Population With Commercial or Medicare Advantage (MA) Insurance
Mar 10, 2025, 14:00 PM
